Because MICA and MICB are highly expressed in a wide variety of tumor cells, targeting the CD6/CD318 axis with UMCD6 represents a broadly applicable approach to cancer immunotherapy that boosts cancer cell killing by multiple downstream effects on cytotoxic lymphocyte gene expression and effector function. Here, CD6 is linked to cancer.